Recruitment

Recruitment Status
Unknown status

Inclusion Criteria

WHO activity score between 0 and 2.
NSCLC proved by a histological biopsy
age over superior to 18
...
WHO activity score between 0 and 2.
NSCLC proved by a histological biopsy
age over superior to 18
indication of erlotinib therapy after at least one previous therapy
life expectancy exceeding 12 weeks
patients who have signed an informed consent to participate in this study
EGFR mutation status known with no activating EGFR mutation

Exclusion Criteria

other malignant disease
infection with the HIV virus
contraindication for the initiation of erlotinib
...
other malignant disease
infection with the HIV virus
contraindication for the initiation of erlotinib
refusal to sign the consent
progressive inflammatory disease
life expectancy less than 12 weeks
major adults protected by French law

Summary

Conditions
  • No EGFR Activating Mutation
  • Non-small Cell Lung Cancer Metastatic or Non-small Cell Lung Cancer Recurrent
Type
Interventional
Phase
Phase 2
Design
  • Allocation: N/A
  • Intervention Model: Single Group Assignment
  • Masking: None (Open Label)

Participation Requirements

Age
Between 18 years and 125 years
Gender
Both males and females

Inclusion Criteria

WHO activity score between 0 and 2.
NSCLC proved by a histological biopsy
age over superior to 18
...
WHO activity score between 0 and 2.
NSCLC proved by a histological biopsy
age over superior to 18
indication of erlotinib therapy after at least one previous therapy
life expectancy exceeding 12 weeks
patients who have signed an informed consent to participate in this study
EGFR mutation status known with no activating EGFR mutation

Exclusion Criteria

other malignant disease
infection with the HIV virus
contraindication for the initiation of erlotinib
...
other malignant disease
infection with the HIV virus
contraindication for the initiation of erlotinib
refusal to sign the consent
progressive inflammatory disease
life expectancy less than 12 weeks
major adults protected by French law

Locations

Angers, Maine et Loire, 49933
Nancy, Meurthe et Moselle, 54000
Percy, Haut de Seine, 92140
Toulouse, Haute Garonne, 31000
Bordeaux, Gironde, 33000
...
Angers, Maine et Loire, 49933
Nancy, Meurthe et Moselle, 54000
Percy, Haut de Seine, 92140
Toulouse, Haute Garonne, 31000
Bordeaux, Gironde, 33000
Rouen, Seine maritime, 76000
Créteil, Val de Marne, 94000
Tours, Indre et Loire, 37000

Tracking Information

NCT #
NCT02069418
Collaborators
  • University Hospital, Tours
  • Army Hospital, Percy
  • Créteil Hospital
  • University Hospital, Rouen
  • Central Hospital, Nancy, France
  • University Hospital, Toulouse
  • University Hospital, Bordeaux
Investigators
  • Principal Investigator: José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers
  • José HUREAUX, MD, PhD University Hospital, Angers Study Chair: Olivier COUTURIER, MD, PhD University Hospital, Angers